While Caccamo et al. provided preclinical data indicating that reducing mTOR signalling may be a valid therapeutic approach for tauopathies, our results suggest that this salvage pathway may already be active in AD patients by up-regulation of miR-100 (fold change 2.17). This evidence concerns the gene MTOR and tauopathy.